Myovant Sciences LtdNYSE:MYOV
- LAST PRICE26.8800
- TODAY'S CHANGE (%)-0.0100 (-0.0372%)
- Bid / Lots26.8700/ 2
- Ask / Lots26.9100/ 1
- Open / Previous Close26.8800 / 26.8900
- Day Range
- 52 Week Range
- Volume280,737
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MYOV |
|---|---|---|
| 09:32 ET | 5516 | 26.89 |
| 09:33 ET | 700 | 26.89 |
| 09:35 ET | 500 | 26.89 |
| 09:37 ET | 11914 | 26.89 |
| 09:39 ET | 300 | 26.89 |
| 09:42 ET | 3100 | 26.885 |
| 09:44 ET | 1061 | 26.89 |
| 09:46 ET | 824 | 26.89 |
| 09:48 ET | 722 | 26.89 |
| 09:50 ET | 1872 | 26.88 |
| 09:51 ET | 1800 | 26.89 |
| 09:55 ET | 600 | 26.885 |
| 09:57 ET | 200 | 26.89 |
| 10:00 ET | 500 | 26.885 |
| 10:02 ET | 3187 | 26.88 |
| 10:04 ET | 300 | 26.885 |
| 10:08 ET | 200 | 26.885 |
| 10:09 ET | 200 | 26.885 |
| 10:11 ET | 200 | 26.89 |
| 10:13 ET | 721 | 26.89 |
| 10:15 ET | 594 | 26.89 |
| 10:18 ET | 1331 | 26.89 |
| 10:20 ET | 400 | 26.885 |
| 10:22 ET | 100 | 26.89 |
| 10:24 ET | 300 | 26.89 |
| 10:26 ET | 100 | 26.885 |
| 10:27 ET | 500 | 26.89 |
| 10:29 ET | 100 | 26.89 |
| 10:31 ET | 1326 | 26.89 |
| 10:33 ET | 3332 | 26.895 |
| 10:36 ET | 200 | 26.9 |
| 10:38 ET | 300 | 26.9 |
| 10:40 ET | 1191 | 26.895 |
| 10:42 ET | 323 | 26.9 |
| 10:44 ET | 400 | 26.9 |
| 10:45 ET | 426 | 26.9 |
| 10:49 ET | 400 | 26.89 |
| 10:51 ET | 900 | 26.9 |
| 10:54 ET | 592 | 26.9 |
| 10:56 ET | 1083 | 26.9 |
| 10:58 ET | 100 | 26.9 |
| 11:00 ET | 200 | 26.9 |
| 11:02 ET | 1525 | 26.9 |
| 11:05 ET | 100 | 26.9 |
| 11:07 ET | 200 | 26.895 |
| 11:09 ET | 500 | 26.9 |
| 11:12 ET | 400 | 26.9 |
| 11:14 ET | 374 | 26.9 |
| 11:16 ET | 705 | 26.895 |
| 11:20 ET | 100 | 26.895 |
| 11:23 ET | 300 | 26.9 |
| 11:39 ET | 499 | 26.9 |
| 11:41 ET | 1343 | 26.9 |
| 11:45 ET | 106 | 26.9 |
| 11:48 ET | 300 | 26.9 |
| 11:50 ET | 200 | 26.9 |
| 11:52 ET | 308 | 26.9 |
| 11:59 ET | 100 | 26.89 |
| 12:12 ET | 100 | 26.9 |
| 12:14 ET | 100 | 26.8999 |
| 12:19 ET | 300 | 26.9 |
| 12:21 ET | 100 | 26.9 |
| 12:32 ET | 100 | 26.89 |
| 12:33 ET | 200 | 26.9 |
| 12:35 ET | 100 | 26.9 |
| 12:39 ET | 400 | 26.895 |
| 12:44 ET | 100 | 26.89 |
| 12:46 ET | 900 | 26.9 |
| 12:51 ET | 1100 | 26.9 |
| 12:53 ET | 100 | 26.895 |
| 12:55 ET | 300 | 26.9 |
| 01:00 ET | 628 | 26.9 |
| 01:02 ET | 100 | 26.9 |
| 01:04 ET | 400 | 26.89 |
| 01:06 ET | 100 | 26.89 |
| 01:08 ET | 150 | 26.896 |
| 01:11 ET | 200 | 26.9 |
| 01:13 ET | 100 | 26.9 |
| 01:15 ET | 11777 | 26.895 |
| 01:18 ET | 300 | 26.89 |
| 01:20 ET | 200 | 26.895 |
| 01:22 ET | 200 | 26.9 |
| 01:24 ET | 100 | 26.89 |
| 01:26 ET | 650 | 26.8928 |
| 01:29 ET | 600 | 26.89 |
| 01:33 ET | 100 | 26.9 |
| 01:42 ET | 100 | 26.89 |
| 01:44 ET | 100 | 26.89 |
| 01:45 ET | 900 | 26.89 |
| 01:49 ET | 100 | 26.89 |
| 01:51 ET | 100 | 26.9 |
| 01:54 ET | 250 | 26.9 |
| 02:00 ET | 600 | 26.89 |
| 02:02 ET | 300 | 26.89 |
| 02:05 ET | 100 | 26.9 |
| 02:07 ET | 100 | 26.9 |
| 02:09 ET | 300 | 26.9 |
| 02:16 ET | 100 | 26.895 |
| 02:23 ET | 300 | 26.89 |
| 02:27 ET | 258 | 26.895 |
| 02:32 ET | 300 | 26.895 |
| 02:34 ET | 1000 | 26.89 |
| 02:41 ET | 100 | 26.895 |
| 02:43 ET | 1669 | 26.895 |
| 02:45 ET | 300 | 26.89 |
| 02:48 ET | 200 | 26.89 |
| 02:52 ET | 100 | 26.89 |
| 02:56 ET | 200 | 26.895 |
| 02:57 ET | 979 | 26.895 |
| 03:01 ET | 1385 | 26.895 |
| 03:03 ET | 100 | 26.9 |
| 03:08 ET | 14712 | 26.895 |
| 03:10 ET | 5616 | 26.895 |
| 03:12 ET | 600 | 26.895 |
| 03:14 ET | 105 | 26.895 |
| 03:15 ET | 6400 | 26.9 |
| 03:17 ET | 200 | 26.9 |
| 03:19 ET | 100 | 26.9 |
| 03:21 ET | 1120 | 26.89 |
| 03:24 ET | 389 | 26.9 |
| 03:28 ET | 1600 | 26.895 |
| 03:30 ET | 689 | 26.895 |
| 03:32 ET | 703 | 26.89 |
| 03:33 ET | 450 | 26.89 |
| 03:35 ET | 533 | 26.89 |
| 03:37 ET | 830 | 26.895 |
| 03:39 ET | 100 | 26.9 |
| 03:42 ET | 1910 | 26.89 |
| 03:44 ET | 900 | 26.895 |
| 03:46 ET | 1475 | 26.89 |
| 03:48 ET | 200 | 26.895 |
| 03:50 ET | 368 | 26.895 |
| 03:51 ET | 11642 | 26.895 |
| 03:53 ET | 1500 | 26.89 |
| 03:55 ET | 19176 | 26.88 |
| 03:57 ET | 5063 | 26.88 |
| 04:00 ET | 81682 | 26.88 |
Jan 26, 2023
BRIEF-Myovant Sciences Announces Corporate Updates And Financial Results For Third Fiscal Quarter 2022, from 5:29PM ET on Thursday Jan 26, 2023 by Thomson Reuters
5:29PM ET on Thursday Jan 26, 2023 by Thomson Reuters-- Earnings Flash (MYOV) MYOVANT SCIENCES Reports Q3 Revenue $100.2M, from 4:06PM ET on Thursday Jan 26, 2023 by MT Newswires
4:06PM ET on Thursday Jan 26, 2023 by MT NewswiresMyovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022, from 4:05PM ET on Thursday Jan 26, 2023 by GlobeNewswire
4:05PM ET on Thursday Jan 26, 2023 by GlobeNewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAFE, LBAI, FCRD, MYOV, from 12:20PM ET on Thursday Jan 26, 2023 by PR Newswire
12:20PM ET on Thursday Jan 26, 2023 by PR Newswire
Jan 20, 2023
Insider Sell: Myovant Sciences, from 4:35PM ET on Friday Jan 20, 2023 by MT Newswires
4:35PM ET on Friday Jan 20, 2023 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Myovant Sciences Ltd | 2.6B | -14.0x | --- |
FibroGen Inc | 2.3B | -6.3x | --- |
Prothena Corporation PLC | 2.8B | -17.3x | --- |
Insmed Inc | 2.9B | -5.9x | --- |
Blueprint Medicines Corp | 2.9B | -3.8x | --- |
CureVac NV | 2.2B | -15.6x | --- |
Company Information
Myovant Sciences Ltd is a biopharmaceutical company. The Company is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company’s two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. It develops Relugolix for the treatment of men with advanced prostate cancer. The Company is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.
Contact Information
- Headquarters
- Ste 1 3rd Fl, 11/12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
- Phone
- 207-400-3351
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Myrtle Potter
- Principal Executive Officer, Director
- David Marek
- Chief Financial and Business Officer, Principal Financial and Accounting Officer
- Uneek Mehra
- General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
- Matthew Lang
- Chief Medical Officer
- Juan Camilo Arjona Ferreira
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
|---|---|
Revenue (TTM) | $379.1M |
Shares Outstanding | 97.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.18 |
EPS | $-1.92 |
Book Value | $-4.99 |
P/E Ratio | -14.0x |
Price/Sales (TTM) | 6.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -38.75% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
